Adicet Bio, Inc. (NASDAQ:ACET) Director Aya Jakobovits sold 1,792 shares of Adicet Bio stock in a transaction dated Thursday, May 20th. The stock was sold at an average price of $14.23, for a total value of $25,500.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Aya Jakobovits also recently made the following trade(s):
- On Tuesday, May 18th, Aya Jakobovits sold 6,208 shares of Adicet Bio stock. The shares were sold at an average price of $14.05, for a total value of $87,222.40.
- On Wednesday, May 12th, Aya Jakobovits sold 10,000 shares of Adicet Bio stock. The shares were sold at an average price of $13.23, for a total value of $132,300.00.
Shares of NASDAQ ACET traded up $0.87 during trading on Thursday, hitting $14.60. The company had a trading volume of 49,314 shares, compared to its average volume of 132,163. The company has a market cap of $464.48 million, a P/E ratio of -1.36 and a beta of 2.43. Adicet Bio, Inc. has a 52 week low of $9.71 and a 52 week high of $21.70. The business’s 50-day moving average is $13.63 and its 200 day moving average is $13.75.
Adicet Bio (NASDAQ:ACET) last posted its quarterly earnings results on Sunday, May 16th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.34). As a group, equities research analysts expect that Adicet Bio, Inc. will post -3.34 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its position in shares of Adicet Bio by 928,800.0% in the fourth quarter. Wells Fargo & Company MN now owns 9,289 shares of the company’s stock worth $130,000 after buying an additional 9,288 shares during the period. Morgan Stanley purchased a new stake in Adicet Bio in the 3rd quarter worth about $115,000. Citigroup Inc. boosted its position in Adicet Bio by 3,698.4% during the 4th quarter. Citigroup Inc. now owns 11,585 shares of the company’s stock worth $163,000 after acquiring an additional 11,280 shares during the period. Golden State Equity Partners acquired a new stake in Adicet Bio during the 4th quarter worth about $184,000. Finally, Jane Street Group LLC acquired a new stake in Adicet Bio during the 1st quarter worth about $238,000. Institutional investors own 46.35% of the company’s stock.
A number of equities analysts have commented on ACET shares. Jonestrading started coverage on Adicet Bio in a research note on Wednesday, May 5th. They issued a “buy” rating and a $33.00 target price for the company. Guggenheim assumed coverage on Adicet Bio in a research note on Wednesday, April 14th. They issued a “buy” rating and a $22.00 target price for the company. HC Wainwright assumed coverage on Adicet Bio in a research report on Thursday, April 29th. They set a “buy” rating and a $27.00 price objective for the company. Canaccord Genuity assumed coverage on Adicet Bio in a research report on Tuesday, April 20th. They set a “buy” rating and a $28.00 price objective for the company. Finally, Zacks Investment Research upgraded Adicet Bio from a “sell” rating to a “hold” rating in a research report on Tuesday. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $27.00.
Adicet Bio Company Profile
Adicet Bio, Inc, a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients.
Featured Story: What defines an oversold asset?
